PHOTOTHERAPORT is set to develop light-based therapies in pre-clinical models to reduce inflammation and neuropathic pain.

Mission

- Use locally emitted light, which delivers anti-inflammatory action by PBM and also allows turning on and off the pharmacological action of photoswitchable drugs locally and on demand. Develop PhotoTheraPorts, light-emitting implants based on upconverting nanoparticles, to illuminate the target sites in the body.

- Create suitable photoswitchable drugs with anti-inflammatory and neuroinhibitory activity and preclinically test the efficacy and safety of both devices and drugs.

- Demonstrate preclinically a novel treatment modality to reduce inflammation and neuroinhibition locally and on demand, in well-established animal models of inflammatory and neuropathic pain (peripheral, spinal cord, brain cingulate cortex) and epilepsy (focal seizures).